文献速递前列腺增生与排尿功能障碍

WATER II研究:Aquablation治疗80-150mL大体积前列腺增生的早期安全性与可行性

WATER II (80-150 mL) procedural outcomes.
PubMed 文献 · BJU Int · 2018-06-10

WATER II是一项多中心前瞻性研究,纳入101例有中重度症状且前列腺体积80-150mL的BPH患者,接受Aquablation治疗。结果显示该技术可行且安全,平均手术时间37分钟,平均住院1.6天,1个月Clavien-Dindo≥2级事件率为29.7%,出血并发症9.9%,围手术期输血5.9%。

要点

  • Aquablation治疗80-150mL大前列腺增生可行且安全。
  • 平均手术时间37分钟,平均住院1.6天。
  • 1个月Clavien-Dindo≥2级事件率29.7%,出血并发症9.9%。

核心结论

  • Aquablation治疗80-150mL大体积前列腺增生患者可行且安全,6个月疗效数据待后续发表。

研究设计与样本

  • 多中心前瞻性国际临床试验(WATER II),2017年9月至12月纳入101例中重度BPH症状且前列腺体积80-150mL的男性患者。
  • 基线人口学和标准化术后管理变量记录于中心独立监查数据库,术者填写术中技术因素和术后管理问卷,1个月内不良事件由独立临床事件委员会裁定。

主要发现

  • 平均(范围)前列腺体积107(80-150)mL。
  • 平均(范围)手术时间37(15-97)分钟,Aquablation切除时间8(3-15)分钟。
  • 34例单次pass即达充分腺瘤切除,67例需额外pass(平均1.8次治疗pass),均在单次手术内完成。
  • 止血采用膀胱内Foley球囊导管牵引(n=98,平均18小时)或前列腺窝球囊直接填塞(n=3,平均15小时),无患者在原手术时需电灼止血。
  • 术后平均住院1.6天(范围同日出院至6天),1个月Clavien-Dindo≥2级事件率29.7%,出血并发症10例(9.9%),包括6例(5.9%)围手术期输血。

临床怎么用

  • 对于80-150mL大体积前列腺增生患者,Aquablation可作为可行的微创治疗选择。
  • 术后止血可采用Foley球囊导管牵引或前列腺窝球囊填塞,通常无需电灼止血。
  • 术后住院时间较短,但需关注1个月内Clavien-Dindo≥2级事件及出血风险。

局限性

  • 仅报告1个月早期安全性和可行性数据,6个月疗效数据尚未获得。
  • 样本量有限(101例),长期疗效和安全性需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To present early safety and feasibility data from a multicentre prospective study (WATER II) of aquablation in the treatment of symptomatic men with large-volume benign prostatic hyperplasia (BPH). METHODS: Between September and December 2017, 101 men with moderate-to-severe BPH symptoms and prostate volume of 80-150 mL underwent aquablation in a prospective multicentre international clinical trial. Baseline demographics and standardized postoperative management variables were carefully recorded in a central independently monitored database. Surgeons answered analogue scale questionnaires on intra-operative technical factors and postoperative management. Adverse events up to 1 month were adjudicated by an independent clinical events committee. RESULTS: The mean (range) prostate volume was 107 (80-150) mL. The mean (range) operating time was 37 (15-97) min and aquablation resection time was 8 (3-15) min. Adequate adenoma resection was achieved with a single pass in 34 patients and with additional passes in 67 patients (mean 1.8 treatment passes), all in a single operating session. Haemostasis was achieved using either a Foley balloon catheter placed in the bladder under traction (n = 98, mean duration 18 h) or direct tamponade using a balloon inflated in the prostate fossa (n = 3, mean duration 15 h). No patient required electrocautery for haemostasis at the time of the primary procedure. The mean length of stay after the procedure was 1.6 days (range same day to 6 days). The Clavien-Dindo grade ≥2 event rate observed at 1 month was 29.7%. Bleeding complications were recorded in 10 patients (9.9%) during the index procedure hospitalization prior to discharge, and included six (5.9%) peri-operative transfusions. CONCLUSIONS: Aquablation is feasible and safe in treating men with men with large prostates (80-150 mL). The 6-month efficacy data are being accrued and will be presented in future publications (ClinicalTrials.gov number, NCT03123250).

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Desai M, Bidair M, Bhojani N, et al. WATER II (80-150 mL) procedural outcomes. BJU Int. 2018. PMID: 29694702. doi:10.1111/bju.14360

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。